Ledger · 2026-08-29 · Biotechnology

AHPND-Targeting Bacteriophage Suspensions via Rapid Broth Fermentation

Rejected

This concept did not clear the framework. The reasoning is published in full below.

Why it failed

• Negative control used as incumbent
• Below the 2x step-change bar

Assessment

Produces targeted lytic bacteriophage suspensions via benchtop broth fermentation to eradicate AHPND-causing Vibrio parahaemolyticus, nearly doubling shrimp crop survival rates over conventional care. Operates at an 83.8% gross margin with $85,000 startup CapEx.

Claimed advantage

Shrimp survival rate post-AHPND challenge: Antibiotics / No Treatment ~45% vs Phage Therapy ~78.5% to 90.9% (>1.7x to 2x superior)

Named comparator: Aquaculture probiotics / Antibiotics

Also flagged

• Evidence rests on non-peer-reviewed sources
• Duplicate references inflating the evidence base
• Price parity asserted, not sourced

A rejection is not a claim that the science is wrong. It means the venture case did not survive: the comparator was not what the buyer actually buys, the comparison was not like-for-like, the advantage fell short of a step change, or the capital and time to first revenue were prohibitive.

---

Assessed 2026-08-29 against seven gates plus the voiding sub-tests. How the method works · Browse all concepts